Home
About Us
Seglin Technology
Programmes
Investors
News Centre
Careers
Contact Us
News Centre
Press Releases
Latest
2011
2010
2009
2008
2007
2006
2005
2004
Events
Home
...
News Centre
...
Press Releases
Press Releases
2006 Press Releases VASTox Acquires Key Assets from MNL Pharma
Released 14th December 2006
VASTox's drug discovery pipeline and chemistry service capabilities strengthened by acquisition of MNL Pharma's key assets.
2006 Spinal Muscular Atrophy Programme Receives Grant from Leading Neuromuscular Charity
Released 1st November 2006
VASTox Announces Promising Results in Spinal Muscular Atrophy Drug Discovery Programme
Released 17th October 2006
VASTox Host Analyst Day
Released 6th October 2006
Interim Results for the Six Months Ended 31 July 2006
Released 26th September 2006
VASTox Provide Grant to Support DMD Patient Registry
Released 1st August 2006
VASTox has provided a grant to Parent Project UK (PPUK) to support the development and management of its Duchenne Muscular Dystrophy patient registry.
VASTox Strengthens Global Patent Position in Duchenne Muscular Dystrophy
Released 13th July 2006
A wide ranging patent has been granted by the Australian Patent Office relating to VASTox's novel approach towards the treatment of DMD.
Appointment of Chief Commercial Officer
Released 12th July 2006
VASTox announces the appointment of James Taylor to the Board of Directors as the company's new Chief Commercial Officer.
VASTox Becomes a Partner in Neuromuscular Disease Network
Released 31st May 2006
VASTox announces that the European Union has awarded a €10 million grant to the TREAT-NMD network, of which VASTox is a member.
VASTox Appoint Professor George Fleet as Carbohydrate Chemistry Consultant
Released 18th May 2006
Preliminary Results for the Year Ended 31 January 2006
Released 9th May 2006
Appointment of Chief Financial Officer
Released 9th May 2006
VASTox plc announces that Darren Millington ACMA has joined the Board of Directors as Chief Financial Officer.
Appointment of Chief Scientific Officer
Released 26th April 2006
VASTox plc announces the appointment of Dr Richard Storer as Chief Scientific Officer.
Commencement of a fifth proprietary drug discovery programme
Released 11th April 2006
VASTox Plc announces the commencement of a fifth proprietary drug discovery programme which is focused on the Wnt signalling pathway for cancer.
Positive Preclinical Results in the Duchenne Muscular Dystrophy Programme
Released 24th January 2006
